This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Manosuthi, W.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manosuthi, W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2009, p. 4545-4548, Vol. 53, No. 10
0066-4804/09/$08.00+0     doi:10.1128/AAC.00492-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Body Weight Cutoff for Daily Dosage of Efavirenz and 60-Week Efficacy of Efavirenz-Based Regimen in Human Immunodeficiency Virus and Tuberculosis Coinfected Patients Receiving Rifampin {triangledown}

Weerawat Manosuthi,1,2* Somnuek Sungkanuparph,2 Preecha Tantanathip,2 Wiroj Mankatitham,2 Aroon Lueangniyomkul,2 Supeda Thongyen,2 Boonchuay Eampokarap,2 Sumonmal Uttayamakul,2 Pawita Suwanvattana,2 Samroui Kaewsaard,2 Kiat Ruxrungtham,3 for the N2R Study Team

Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi 11000, Thailand,1 Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand,2 The HIV Netherlands-Australia-Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Center, Bangkok, Thailand3

Received 15 April 2009/ Returned for modification 12 July 2009/ Accepted 28 July 2009

Seventy-one human immunodeficiency virus-infected patients with tuberculosis who were receiving a rifampin (rifampicin)-containing regimen were initiated on treatment with efavirenz at 600 mg/day plus stavudine-lamivudine. Fasting efavirenz concentrations at 12 h after dosing (C12) were monitored. The mean ± standard deviation efavirenz C12 at weeks 6 and 12 and after rifampin discontinuation were 4.5 ± 4.3, 3.8 ± 3.5, and 3.5 ± 2.7 mg/liter, respectively. High body weight was associated with a low efavirenz C12 at weeks 6 and 12 (P = 0.003, r = –0.255). The efavirenz C12 regression prediction line at 1 mg/liter intercepted a mean body weight of 57.5 kg.

* Corresponding author. Mailing address: Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Tiwanon Road, Nonthaburi 11000, Thailand. Phone: 66-2-5903408. Fax: 66-2-5903411. E-mail: drweerawat{at}hotmail.com

{triangledown} Published ahead of print on 10 August 2009.

Antimicrobial Agents and Chemotherapy, October 2009, p. 4545-4548, Vol. 53, No. 10
0066-4804/09/$08.00+0     doi:10.1128/AAC.00492-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»